NIJBAS
Publications 2024

OPEN ACCESS
ONLINE ISSN: 2992-5797
PRINT ISSN: 2992-6122

NEWPORT INTERNATIONAL JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES (NIJBAS)

Volume 5 Issue 3 2024

https://doi.org/10.59298/NIJBAS/2024/5.3.444811

Adaptive Immunity and Autoimmune Disease: Mechanisms, Pathogenesis, and Therapeutic Approaches

Mugisha Emmanuel K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Autoimmune diseases arise when the adaptive immune system mistakenly targets self-antigens, leading to chronic inflammation and tissue damage. This review explores the mechanisms by which adaptive immunity, particularly T and B lymphocyte responses, contributes to the development and persistence of autoimmune diseases. It examines the underlying factors that influence autoreactivity, including genetic susceptibility, environmental triggers, and breakdowns in immune tolerance. Additionally, we discuss the role of T cells, B cells, and autoantibodies in various autoimmune diseases, with emphasis on rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, and multiple sclerosis. Insights into the molecular and cellular pathways driving autoimmunity have informed current therapeutic strategies, including immune modulation and targeted biologics. This review highlights the challenges of restoring tolerance in autoimmune disease management and outlines future directions for research and therapeutic development.

Keywords: Adaptive immunity, autoimmunity, T cells, B cells, immune tolerance, autoimmune diseases

INTRODUCTION

Adaptive immunity is an essential component of the immune system that provides long-term, highly specific protection against pathogens through the coordinated actions of T and B lymphocytes [1]. Unlike innate immunity, which offers rapid but non-specific defenses, adaptive immunity learns to recognize specific antigens and remembers them for future encounters. However, this remarkable specificity and memory can sometimes malfunction, leading the immune system to attack the body's own tissues. Autoimmune diseases arise when adaptive immunity mistakenly targets self-antigens, causing chronic inflammation, tissue damage, and a range of debilitating symptoms. Conditions like rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type 1 diabetes (T1D), and multiple sclerosis (MS) are well-known autoimmune diseases, each associated with particular autoantigens and distinctive pathological features [2]. The development of autoimmune diseases is influenced by multiple factors, including genetic predispositions, environmental triggers, and immune dysregulation [3]. Individuals with specific genetic variants, particularly in immune-regulating genes, are at higher risk of autoimmune diseases due to changes in how self-antigens are recognized and processed [4]. Environmental factors, such as infections, can also contribute by triggering immune responses that may cross-react with self-tissues, a phenomenon known as molecular mimicry [5]. Furthermore, immune tolerance, the system's ability to recognize and ignore self-antigens, often fails in autoimmune diseases, allowing autoreactive T and B cells to persist and cause tissue damage [6]. Understanding the underlying mechanisms of adaptive immunity in autoimmune disease pathogenesis has led to significant advances in therapeutic strategies, including immune modulation and targeted biologics. By exploring the pathways and cellular processes that contribute to autoimmunity, researchers are working toward treatments that can effectively reduce disease severity while preserving immune function. This review provides an overview of the role of adaptive immunity in autoimmune diseases, emphasizing mechanisms, clinical implications, and emerging therapeutic approaches aimed at restoring immune tolerance.

OPEN ACCESS
ONLINE ISSN: 2992-5797
PRINT ISSN: 2992-6122

2. Mechanisms of Self-Tolerance and Autoimmunity

2.1 Central and Peripheral Tolerance

Self-tolerance is essential in adaptive immunity, preventing the immune system from attacking the body's own cells. It is established through two primary mechanisms: central and peripheral tolerance.

Central Tolerance develops in the thymus and bone marrow, where T and B cells undergo stringent selection processes to eliminate autoreactivity [7]. In the thymus, T cells that strongly recognize self-antigens are either deleted or differentiate into regulatory T cells (Tregs), which exert immune-suppressive functions to maintain tolerance [8]. Similarly, B cells in the bone marrow that demonstrate high-affinity self-reactivity undergo receptor editing or are deleted, significantly reducing the pool of potentially autoreactive cells [9].

Peripheral Tolerance operates in tissues outside of the primary lymphoid organs, providing a secondary checkpoint to control any autoreactive T and B cells that escape central tolerance. Mechanisms include anergy, where cells become functionally unresponsive, Treg-mediated suppression, which actively inhibits autoimmune reactions, and activation-induced cell death, where autoreactive cells are eliminated [10]. Together, these processes maintain immune homeostasis, ensuring the immune system selectively targets harmful pathogens while protecting self-tissues.

2.2 Breakdown of Tolerance in Autoimmune Disease

Autoimmune diseases arise when these tolerance mechanisms fail, allowing autoreactive T and B cells to become activated. Factors contributing to tolerance breakdown include:

Genetic Susceptibility: Genetic polymorphisms in immune-regulating genes, such as HLA alleles, contribute to increased susceptibility to autoimmune diseases by altering antigen presentation or immune regulation [11].

Environmental Triggers: Infections, hormonal changes, and environmental toxins can act as triggers, potentially initiating or exacerbating autoimmune responses. Molecular mimicry, where pathogen antigens resemble self-antigens, can prompt cross-reactive immune responses [12].

2.2 Breakdown of Tolerance in Autoimmune Disease

Autoimmune diseases occur when tolerance mechanisms fail, allowing autoreactive T and B cells to target self-tissues. Several factors contribute to this breakdown of tolerance:

Genetic Susceptibility: Certain genetic polymorphisms, especially in immune-regulating genes such as those encoding HLA alleles, increase susceptibility to autoimmune diseases [13]. These genetic variations can disrupt antigen presentation or alter immune regulatory pathways, creating an environment conducive to autoimmunity.

Environmental Triggers: Infections, hormonal shifts, and environmental toxins are recognized triggers of autoimmune responses [14]. In some cases, pathogens contain antigens structurally similar to self-antigens, a phenomenon called molecular mimicry, which can lead to cross-reactive immune responses. This mimicry can confuse the immune system, resulting in the misidentification of self-tissues as foreign [15].

Immune Dysregulation: Failures in regulatory immune pathways can also contribute to tolerance breakdown. When regulatory T cells (Tregs) are deficient or dysfunctional, they fail to suppress autoreactive cells, allowing immune responses against self-antigens. This disruption in immune balance can lead to persistent inflammation and tissue damage, hallmark features of autoimmune diseases [16].

B Cells and Autoantibodies

B cells play a key role in autoimmunity by producing autoantibodies and acting as antigen-presenting cells.

Autoantibody Production: In autoimmune diseases, B cells often produce autoantibodies that target self-antigens, forming immune complexes [3]. These complexes activate the complement system, leading to inflammation and tissue damage. For example, in systemic lupus erythematosus (SLE), anti-nuclear antibodies bind to DNA and nuclear proteins, causing widespread damage [17]. Antigen Presentation and Cytokine Production: B cells also present self-antigens to T cells, stimulating their activation and enhancing the autoimmune response [18]. Additionally, B cells secrete pro-inflammatory cytokines that further amplify immune activity, promoting chronic inflammation and contributing to disease progression [9].

4.Pathogenesis of Select Autoimmune Diseases

4.1 Rheumatoid Arthritis (RA)

Rheumatoid arthritis (RA) is a chronic autoimmune disease primarily affecting the joints but can also involve systemic symptoms. Both T and B cells are crucial in RA pathogenesis, with Th17 cells driving inflammation in the synovial membrane. B cells produce rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs), which bind to joint tissues, forming immune complexes [19,20]. These complexes activate complement pathways, promoting inflammation and ultimately causing joint erosion and cartilage destruction.

4.2 Systemic Lupus Erythematosus (SLE)

Systemic lupus erythematosus (SLE) is characterized by the production of autoantibodies against nuclear components like DNA and RNA [17]. These autoantibodies form immune complexes that deposit in organs, such as the kidneys, skin, and brain. Complement activation by these complexes results in widespread inflammation and tissue damage, with nephritis, rashes, and neuropsychiatric symptoms being common manifestations.

OPEN ACCESS
ONLINE ISSN: 2992-5797
PRINT ISSN: 2992-6122

4.3 Type 1 Diabetes (T1D)

In type 1 diabetes (T1D), autoreactive CD8+ T cells attack insulin-producing beta cells in the pancreas. This destruction, primarily T cell-mediated, leads to a gradual loss of insulin production, necessitating lifelong insulin replacement to regulate blood glucose levels [21]. T1D illustrates how autoimmune responses can target a single organ, impacting metabolic homeostasis.

4.4 Multiple Sclerosis (MS)

Multiple sclerosis (MS) involves immune-mediated destruction of the myelin sheath surrounding nerve fibers in the central nervous system. Th17 and Th1 cells contribute to the inflammatory process, leading to demyelination and neuronal injury [22]. This loss of myelin impairs neural transmission, resulting in progressive neurological dysfunction and disability.

5. Therapeutic Approaches to Autoimmune Diseases

5.1 Immunosuppressive Therapies

Traditional immunosuppressive therapies, including corticosteroids and non-specific immunosuppressants, aim to reduce immune system overactivity and manage inflammation [23]. While effective in managing symptoms, these therapies lack specificity, potentially leading to increased susceptibility to infections and other side effects due to broad immune suppression.

5.2 Targeted Biologic Therapies

Biologic therapies, such as TNF-α inhibitors for rheumatoid arthritis (RA) and IL-17 inhibitors for Th17-mediated diseases, offer targeted approaches by focusing on specific immune molecules implicated in autoimmune activity [24]. By selectively blocking inflammatory pathways, biologics provide more precise treatments; however, they can still pose risks of immune-related side effects, such as infections or immune dysregulation.

5.3 Immune Tolerance Induction

New therapeutic approaches aim to restore immune tolerance to self-antigens by enhancing regulatory T cells (Tregs) or utilizing antigen-specific therapies. Techniques such as Treg adoptive transfer or antigen-based therapies seek to re-establish self-tolerance without broadly compromising immune function [25]. These strategies offer promise for reducing autoimmune activity with fewer adverse effects compared to traditional therapies.

5.4 Gene Therapy and Personalized Medicine

With advances in gene editing and personalized medicine, treatments for autoimmune diseases are becoming more individualized. Gene therapy approaches that target immune-regulating genes or modify pathways involved in autoimmunity offer potential for long-term management [26]. Additionally, personalized treatments based on individual immune profiles could allow for therapies that are both highly specific and durable, representing a significant shift toward tailored and potentially curative strategies [27].

6. Future Directions

The complexity of autoimmune diseases necessitates a continued focus on identifying the molecular and cellular mechanisms underlying autoreactivity and tolerance breakdown. Research into individualized treatment approaches, improved biomarker identification, and strategies to enhance immune tolerance are critical areas of focus. Advances in immunogenetics, high-throughput sequencing, and bioinformatics are anticipated to play pivotal roles in understanding the precise mechanisms of adaptive immunity in autoimmunity, paving the way for novel and effective therapeutic interventions.

CONCLUSION

Adaptive immunity plays a dual role in both defending against infections and, when dysregulated, contributing to autoimmune diseases. The interplay between genetic factors, environmental triggers, and immune regulation is fundamental to understanding autoimmune pathogenesis. Advances in understanding T cell and B cell function, immune tolerance mechanisms, and therapeutic modulation have significantly shaped autoimmune disease management. As research progresses, therapies targeting specific immune pathways and restoring immune tolerance offer promising avenues for improved outcomes in autoimmune disease patients.

REFERENCES

1. Wang R, Lan C, Benlagha K, Camara NO, Miller H, Kubo M, Heegaard S, Lee P, Yang L, Forsman H, Li X. The interaction of innate immune and adaptive immune system. MedComm. 2024 Oct;5(10):e714.
2. Alum EU, Ibiam UA, Ugwu OPC. A Comprehensive Review of Treatment Approaches and Perspectives for Management of Rheumatoid Arthritis. *INOSR Scientific Research.* 2023; 10(1):12-17. https://doi.org/10.59298/INOSRSR/2023/2.2.13322
3. Pisetsky DS. Pathogenesis of autoimmune disease. Nature Reviews Nephrology. 2023 Aug;19(8):509-24.
4. Alum EU, Ugwu OPC. Nutritional Strategies for Rheumatoid Arthritis: Exploring Pathways to Better Management. *INOSR Scientific Research.* 2023; 10(1):18-26. https://doi.org/10.59298/INOSRSR/2023/3.2.47322

OPEN ACCESS
ONLINE ISSN: 2992-5797
PRINT ISSN: 2992-6122

5. HAVUZ SG. CHAPTER TWENTY-ONE THE EFFECT OF INFECTIOUS DISEASES ON AUTOIMMUNITY. Human Autoimmunity and Associated Diseases. 2021 May 18:313.
6. Mezgebu E, Aliy A, Worku T. Autoimmunity and immune tolerance: A review. 2023.
7. Valdes AZ. Immunological tolerance and autoimmunity. InTranslational Autoimmunity 2022 Jan 1 (pp. 325-345). Academic Press.
8. Sakaguchi S, Kawakami R, Mikami N. Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective. Immunotherapy Advances. 2023 Jan 1;3(1):ltad007.
9. Lee S, Ko Y, Kim TJ. Homeostasis and regulation of autoreactive B cells. Cellular & molecular immunology. 2020 Jun;17(6):561-9.
10. Xing Y, Hogquist KA. T-cell tolerance: central and peripheral. Cold Spring Harbor perspectives in biology. 2012 Jun 1;4(6):a006957.
11. Li HF, Hong Y, Zhang X, Xie Y, Skeie GO, Hao HJ, Gilhus NE, Liang B, Yue YX, Zhang XJ, Gao X. Gene polymorphisms for both auto-antigen and immune-modulating proteins are associated with the susceptibility of autoimmune myasthenia gravis. Molecular neurobiology. 2017 Aug;54:4771-80.
12. Root-Bernstein R. A General Theory of Autoimmune Disease Causation: Integrating Innate and Adaptive Immunity, Altered Antigen Processing, Sex and Genetic Predispositions, and Microbiome Effects.
13. Hsieh MJ, Tsai PH, Chiang PH, Kao ZK, Zhuang ZQ, Hsieh AR, Ho HL, Chiou SH, Liang KH, Chen YC. Genomic insights into mRNA COVID-19 vaccines efficacy: Linking genetic polymorphisms to waning immunity. Human Vaccines &Immunotherapeutics. 2024 Dec 31;20(1):2399382.
14. Utkurovna SG, Farkhodovna KF, Orifjonovna OF. Features of immune mechanisms in the development of pathological processes. Достижениянауки и образования. 2022(2 (82)):108-15.
15. Neamţu M, Bild V, Vasincu A, Arcan OD, Bulea D, Ababei DC, Rusu RN, Macadan I, Sciucă AM, Neamţu A. Inflammasome Molecular Insights in Autoimmune Diseases. Current Issues in Molecular Biology. 2024 Apr 18;46(4):3502-32.
16. Goswami TK, Singh M, Dhawan M, Mitra S, Emran TB, Rabaan AA, Mutair AA, Alawi ZA, Alhumaid S, Dhama K. Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders–Advances and challenges. Human vaccines &immunotherapeutics. 2022 Jan 31;18(1):2035117.
17. Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nature Reviews Rheumatology. 2020 Oct;16(10):565-79.
18. Jang S, Kwon EJ, Lee JJ. Rheumatoid arthritis: pathogenic roles of diverse immune cells. International journal of molecular sciences. 2022 Jan 14;23(2):905.
19. Ibiam UA, Alum EU, Orji OU, Aja PM, Ezeani NN, Ugwu OPC, et al. Anti- Inflammatory Effects of *Buchholzia coriacea* Ethanol Leaf-Extract and Fractions in Freund's Adjuvant-Induced Rheumatoid Arthritic Albino Rats. *Indo American Journal of Pharmaceutical Sciences (IAJPS).* 2018; **5** (7): 6341- 6357. https://doi.org/10.5281/zenodo.1311167.
20. Aloke C, Ibiam UA, Obasi NA, Orji OU, Ezeani NN, Aja PM, et al. Effect of ethanol and aqueous extracts of seed pod of Copaifera salikounda (Heckel) on complete Freund's adjuvant-induced rheumatoid arthritis in rats. J Food Biochem. 2019 Jul;43(7):e12912. doi: 10.1111/jfbc.12912. Epub 2019 May 23. PMID: 31353723.
21. Bjelobaba I, Savic D, Lavrnja I. Multiple sclerosis and neuroinflammation: the overview of current and prospective therapies. Current pharmaceutical design. 2017 Feb 1;23(5):693-730.
22. Strzelec M, Detka J, Mieszczak P, Sobocińska MK, Majka M. Immunomodulation—a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system. Frontiers in Immunology. 2023 Mar 9;14:1127704.
23. Küster D, Spuls PI, Flohr C, Smith C, Hooft L, Deckert S, Schwennesen T, Roekevisch E, Schmitt J. Effects of systemic immunosuppressive therapies for moderate-to-severe eczema in children and adults. The Cochrane Database of Systematic Reviews. 2018 Aug;2018(8).
24. Ţiburcă L, Bembea M, Zaha DC, Jurca AD, Vesa CM, Raţiu IA, Jurca CM. The treatment with interleukin 17 inhibitors and immune-mediated inflammatory diseases. Current Issues in Molecular Biology. 2022 Apr 26;44(5):1851-66.
25. Rathod S. Novel insights into the immunotherapy-based treatment strategy for autoimmune type 1 diabetes. Diabetology. 2022 Feb 7;3(1):79-96.
26. Eggenhuizen PJ, Ng BH, Ooi JD. Treg enhancing therapies to treat autoimmune diseases. International journal of molecular sciences. 2020 Sep 23;21(19):7015.
27. Wang RC, Wang Z. Precision medicine: disease subtyping and tailored treatment. Cancers. 2023 Jul 28;15(15):3837.

OPEN ACCESS
ONLINE ISSN: 2992-5797
PRINT ISSN: 2992-6122

CITE AS: Mugisha Emmanuel K. (2024). Adaptive Immunity and Autoimmune Disease: Mechanisms, Pathogenesis, and Therapeutic Approaches. NEWPORT INTERNATIONAL JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES, 5(3):44-48. https://doi.org/10.59298/NIJBAS/2024/5.3.444811